Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
InnovationHealthcareTrouble Ahead For GLP-1 Drugs As Health Plans Stop PayingByBruce Japsen,Senior Contributor.Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy.Follow AuthorJun 09, 2026, 09:00am EDTPhoto Illustration of the new Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, Victoza and Wegovy. Its a prescription medicine used with a reduced calorie diet and physical activity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)UCG/Universal Images Group via Getty ImagesMore employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.A survey of benefits executives at more than 235 employers, health plans and unions showed nearly half, or 49%, or firms who do not currently cover GLP-1s for obesity would “not do so at any price,” Pharmaceutical Strategies Group said in a statement accompanying its 2026 Trends in Drug Benefits Report released Tuesday. Meanwhile, 9 in 10 of the respondents from plans with a median of 14,000 enrollees, said they were “moderately” or “very concerned” about the affordability of GLP-1 therapies for the plan. “As drug costs climb, payers are under pressure to re-evaluate benefit design and cost management strategies,” said Morgan Lee, Vice President of Research and Marketing at PSG. “The debate around GLP-1 coverage is a prime example of the balancing act benefits leaders face as they navigate skyrocketing demand, affordability concerns, and uncertainty around long-term patient outcomes.” Just last week, Cigna confirmed it was no longer covering GLP-1 weight loss drugs for its own employees effective July 1. The change, however, doesn’t impact coverage of the prescriptions for the treatment of type-2 diabetes. Cigna is acting like about 95 percent of employers that the PSG report says cover G...المصدر: Forbes | Source: Forbes
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة Forbes. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by Forbes. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.




